

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/620,820
Filing Date	07/21/2000
First Named Inventor	Alan D. Attie
Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	960296.97290

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.Q./ ↓		BRAUN, A., et al., "Loss of SR-BI Expression leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease...", Cir. Res. 90:270-276 (2002)	
		BRESLOW, J.L., et al., "Transgenic Mouse Models of Lipoprotein Metabolism and Atherosclerosis," Proc. Natl. Acad. Sci. USA 90:8314-8318 (1993)	
		CLEE, S.M., et al., "The Genetic Landscape of type 2 Diabetes in Mice," Endocrine Reviews 28:48-83 (2007)	
		DE WINTHER, M.P.J., et al, "New mouse models for lipoprotein metabolism and atherosclerosis," Current Opinion in Lipidology 13:191-197 (2002)	
		GRASS, D.S., et al, "Transgenic mice expressing both human apolipoprotein B and human CETP...", Journal of lipid Research 36:1082-1091 (1995)	
		HERRERA, V.L.M., et al., "Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival...", Nature medicine 5:1383-1389 (1999)	
		MARSCHANG, P., et al., "Mouse models as tools for dissecting disorders of lipoprotein metabolism," Cell & Developmental Biology 14:25-35 (2003)	
		MASUCCI-MAGOULAS, L., et al., "A mouse model with features of familial combined hyperlipidemia," Science 275:391-394 (1997)	
		MELMAN, A., et al., "hMaxi-K Gene Transfer in Males with Erectile Dysfunction: Results of the First Human Trial," Human Gene Therapy 18:1165-1176 (2006)	
↓		SHARPLESS, N.E., et al., "The mighty mouse: genetically engineered mouse models in cancer drug development," Nature Rev. Drug Discovery 5:741-754 (2006)	

Examiner
Signature

/Celine Qian/


Date
Considered

05/03/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/620,820
				Filing Date	07/21/2000
				First Named Inventor	Alan D. Attie
				Art Unit	1636
				Examiner Name	Celine X. Qian
Sheet	2	of	2	Attorney Docket Number	960296.97290

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/C.Q./ ↓ ↓ ↓		TAKAHASHI, H., et al, "Effect of CETP on the Plasma Lipoprotein Profile in Four Strains of Transgenic Mouse," Biochemical and Biophysical Res. Com. 283:118-123 (2001)		
		ZHANG, S., et al., "Diet-Induced occlusive Coronary Atherosclerosis, Myocardial Infarction...", Circulation 111:3457-3464 (2005)		
		KAHLE, P.J., et al., "The emerging utility of animal models of chronic neurodegenerative diseases," Emerging Therapeutic Targets 5:125-132 (2001)		
		WARRINGTON K.H., Jr., et al., "Treatment of human disease by adeno-associated viral gene transfer," Hum Genet 119:571-603 (2006)		

Examiner Signature	Celine Qian <small>Digitally signed by Celine Qian DN: cn=Celine Qian, c=US, o=USPTO, ou=USPTO, email=celine.qian@uspto.gov Date: 2007.05.03 11:56:57 -0400</small>	Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.